Leo Greenberg

Skadden

Associate, Boston

Tax



T: 617.573.4853 leonard.greenberg@skadden.com

Education

LL.M., Boston University School of Law, 2018

J.D., Boston University School of Law, 2018 (summa cum laude)

A.B., Tufts University, 2012 (magna cum laude)

Bar AdmissionsMassachusetts

Leo Greenberg represents domestic and international clients in an array of U.S. federal income tax matters. Mr. Greenberg advises public and private companies across industries on the buy-side and sell-side tax aspects of mergers and acquisitions. He also counsels multinational companies in the biopharmaceutical, technology, automotive, entertainment, insurance, energy, food and shipping industries on complex post-acquisition integration and cross-border tax planning. Additionally, Mr. Greenberg represents business clients in the tax aspects of public and private debt and equity offerings, redemptions, restructurings, intellectual property licensing and collaboration transactions, and bankruptcies.

In recognition of his work, Mr. Greenberg has been named one of *Best Lawyers*' Ones To Watch in America and an Up & Coming Lawyer by *Massachusetts Lawyers Weekly*.

Representative matters include:

- Acrisure LLC in its sale of convertible senior preferred stock in a \$2.1 billion capital raise led by Bain Capital
- Ambrx Biopharma in its \$2 billion acquisition by Johnson & Johnson
- Aspen Technology, Inc. in its \$11 billion mixed consideration business combination with the software business of Emerson Electric Co.
- CC Capital in its \$250 million investment in The Westaim Corporation
- CF Industries Holdings, Inc. in its \$1.675 billion acquisition of an ammonia production complex located in Waggaman, Louisiana, from Incitec Pivot Limited
- Convera in its \$910 million acquisition of Western Union Business Solutions
- Corix Infrastructure in its merger of equals with SouthWest Water Company
- CureVac N.V. in its \$1.25 billion all-stock acquisition by BioNTech SE
- IVERIC Bio, Inc. in its \$5.9 billion acquisition by Astellas Pharma Inc.
- Jabil Inc. on the \$2.2 billion divestment of its mobility business to BYD Electronic (International) Company Limited
- The McClatchy Company in its Chapter 11 bankruptcy and Section 363 asset sale
- New Fortress Energy Inc. in its:
 - \$5 billion stock and cash acquisition of Hygo Energy Transition Ltd. and Golar LNG Partners LP
 - \$3 billion equity and debt refinancing transactions
- R1 RCM Inc. in its \$8.9 billion acquisition by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice
- Strongbridge Biopharma plc in its acquisition by Xeris Pharmaceuticals, Inc. for stock and contingent value rights
- TTAM Research Institute in its \$305 million acquisition of substantially all the assets of 23andMe Holding Co.
- Zurich Insurance Group in its \$600 million acquisition of the personal travel insurance business of AIG

Mr. Greenberg also regularly advises nonprofit organizations *pro bono* regarding obtaining and maintaining tax-exempt status. Additionally, he is a co-author of the United States chapter of *The Inward Investment and International Taxation Review*.